Marija Zeremski1, Rositsa B Dimova2, Jaroslaw Pillardy3, Ype P de Jong1, Ira M Jacobson4, Andrew H Talal5. 1. Division of Gastroenterology and Hepatology, Weill Cornell Medical College. 2. Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine Department of Biostatistics, State University of New York, Buffalo. 3. Institute for Biotechnology, Cornell University, Ithaca, New York. 4. Icahn School of Medicine at Mount Sinai, New York. 5. Division of Gastroenterology and Hepatology, Weill Cornell Medical College Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine.
Abstract
BACKGROUND: Fibrosis progression varies markedly in hepatitis C virus (HCV)-infected individuals. We investigated factors that influence fibrosis progression in chronic HCV infection. METHODS: HCV-infected patients who underwent at least 2 liver biopsies were included in this study. Associations between fibrosis progression and epidemiologic, virologic, and disease-associated factors were analyzed using logistic regression and multistate Markov modeling. RESULTS: We analyzed 936 biopsy specimens obtained from 378 individuals. Mean age (±SD) at first biopsy was 48.3 ± 9.3 years, 59.3% of patients were male, 59.9% were white, and 86.7% were infected with HCV genotype 1. Fibrosis progression and cirrhosis occurred in 57.4% and 5.8%, respectively. Fibrosis progression between the first and last biopsies was associated with lower fibrosis in the first biopsy specimen (P < .001) and with the occurrence of at least 1 flare in the alanine aminotransferase (ALT) level (>200 U/L; P = .007). We found the highest fibrosis progression rate between stages 0 and 1 and the lowest between stages 2 and 3. Increased necroinflammation and higher ALT level were associated with faster progression. HCV genotype 3-infected patients were more likely to progress to cirrhosis (P < .001). CONCLUSIONS: Fibrosis progression in HCV is not linear but varies according to stage, with the highest progression in patients with the lowest fibrosis severity. Patients who experience flares in the ALT level are also more likely to progress.
BACKGROUND:Fibrosis progression varies markedly in hepatitis C virus (HCV)-infected individuals. We investigated factors that influence fibrosis progression in chronic HCV infection. METHODS:HCV-infectedpatients who underwent at least 2 liver biopsies were included in this study. Associations between fibrosis progression and epidemiologic, virologic, and disease-associated factors were analyzed using logistic regression and multistate Markov modeling. RESULTS: We analyzed 936 biopsy specimens obtained from 378 individuals. Mean age (±SD) at first biopsy was 48.3 ± 9.3 years, 59.3% of patients were male, 59.9% were white, and 86.7% were infected with HCV genotype 1. Fibrosis progression and cirrhosis occurred in 57.4% and 5.8%, respectively. Fibrosis progression between the first and last biopsies was associated with lower fibrosis in the first biopsy specimen (P < .001) and with the occurrence of at least 1 flare in the alanine aminotransferase (ALT) level (>200 U/L; P = .007). We found the highest fibrosis progression rate between stages 0 and 1 and the lowest between stages 2 and 3. Increased necroinflammation and higher ALT level were associated with faster progression. HCV genotype 3-infected patients were more likely to progress to cirrhosis (P < .001). CONCLUSIONS:Fibrosis progression in HCV is not linear but varies according to stage, with the highest progression in patients with the lowest fibrosis severity. Patients who experience flares in the ALT level are also more likely to progress.
Authors: Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole Journal: Clin Gastroenterol Hepatol Date: 2011-03-11 Impact factor: 11.382
Authors: Daniel S Fierer; Alison J Uriel; Damaris C Carriero; Arielle Klepper; Douglas T Dieterich; Michael P Mullen; Swan N Thung; M Isabel Fiel; Andrea D Branch Journal: J Infect Dis Date: 2008-09-01 Impact factor: 5.226
Authors: Marc G Ghany; David E Kleiner; Harvey Alter; Edward Doo; Farooq Khokar; Kittichai Promrat; David Herion; Yoon Park; T Jake Liang; Jay H Hoofnagle Journal: Gastroenterology Date: 2003-01 Impact factor: 22.682
Authors: Vincent Lo Re; Michael J Kallan; Janet P Tate; A Russell Localio; Joseph K Lim; Matthew Bidwell Goetz; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Lesley Park; Robert Dubrow; K Rajender Reddy; Jay R Kostman; Brian L Strom; Amy C Justice Journal: Ann Intern Med Date: 2014-03-18 Impact factor: 25.391
Authors: Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen Journal: JAMA Date: 2012-12-26 Impact factor: 56.272
Authors: Daniel S Fierer; Douglas T Dieterich; M Isabel Fiel; Andrea D Branch; Kristen M Marks; Dahlene N Fusco; Ricky Hsu; Davey M Smith; Joshua Fierer Journal: Clin Infect Dis Date: 2012-12-21 Impact factor: 9.079
Authors: Peter Bacchetti; Ross Boylan; Jacquie Astemborski; Hui Shen; Shruti H Mehta; David L Thomas; Norah A Terrault; Alexander Monto Journal: PLoS One Date: 2011-05-27 Impact factor: 3.240
Authors: Benjamin P Linas; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim Journal: Open Forum Infect Dis Date: 2016-12-27 Impact factor: 4.423
Authors: Geoff McCombe; Davina Swan; Eileen O'Connor; Gordana Avramovic; Peter Vickerman; Zoe Ward; Julian Surey; Juan Macías; John S Lambert; Walter Cullen Journal: JMIR Res Protoc Date: 2018-06-04
Authors: Monica A Konerman; Lauren A Beste; Tony Van; Boang Liu; Xuefei Zhang; Ji Zhu; Sameer D Saini; Grace L Su; Brahmajee K Nallamothu; George N Ioannou; Akbar K Waljee Journal: PLoS One Date: 2019-01-04 Impact factor: 3.240